Fig. 4

Peripheral blood eosinophil counts throughout the course of treatment, from the time of disease diagnosis in the super-responder group of EGPA patients (a) and the responder group (b). Each line represents the mean eosinophil count. Mean values for each patient group were compared by using the Wilcoxon matched-pairs t-test; p < 0.05 was considered statistically significant. †p < 0.01; NS, not significant. Upper brackets at the top show the significance of differences between time of diagnosis versus time of mepolizumab treatment initiation and years 1, 2, 3, and last examination during mepolizumab treatment; lower brackets show the significance of differences between time of initiation of mepolizumab treatment versus years 1, 2, 3, and last examination